
    
      The specific aims are: 1) to evaluate, in a phase I clinical trial, the safety of vaccinating
      patients with dendritic cells transfected with RNA from autologous cancer cells; 2) to
      analyze the T cell responses induced by the treatment; and 3) to improve the efficacy of the
      treatment by developing methods to increase the induction of CD4+T cell responses.
    
  